Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 20819 | 3.2 |
09:34 ET | 530 | 3.2009 |
09:36 ET | 2200 | 3.23 |
09:38 ET | 600 | 3.25 |
09:39 ET | 1558 | 3.25 |
09:41 ET | 3086 | 3.255 |
09:43 ET | 400 | 3.25 |
09:45 ET | 3195 | 3.23 |
09:48 ET | 2976 | 3.2399 |
09:50 ET | 600 | 3.23 |
09:52 ET | 400 | 3.22 |
09:54 ET | 5675 | 3.2197 |
09:56 ET | 2461 | 3.205 |
09:57 ET | 865 | 3.22 |
09:59 ET | 2239 | 3.21 |
10:01 ET | 700 | 3.21 |
10:03 ET | 2960 | 3.2175 |
10:06 ET | 820 | 3.215 |
10:08 ET | 200 | 3.22 |
10:10 ET | 300 | 3.22 |
10:12 ET | 2847 | 3.22 |
10:14 ET | 2854 | 3.225 |
10:15 ET | 1914 | 3.225 |
10:17 ET | 6667 | 3.205 |
10:19 ET | 100 | 3.21 |
10:21 ET | 2536 | 3.2 |
10:24 ET | 1783 | 3.19 |
10:26 ET | 6977 | 3.23 |
10:28 ET | 2691 | 3.23 |
10:30 ET | 200 | 3.23 |
10:32 ET | 1978 | 3.215 |
10:33 ET | 762 | 3.22 |
10:35 ET | 100 | 3.22 |
10:37 ET | 1400 | 3.23 |
10:39 ET | 3256 | 3.235 |
10:42 ET | 599 | 3.235 |
10:44 ET | 2805 | 3.23 |
10:46 ET | 300 | 3.23 |
10:48 ET | 2084 | 3.23 |
10:50 ET | 4204 | 3.225 |
10:51 ET | 418 | 3.215 |
10:53 ET | 426 | 3.215 |
10:55 ET | 3750 | 3.205 |
10:57 ET | 3250 | 3.215 |
11:02 ET | 8606 | 3.215 |
11:04 ET | 2373 | 3.205 |
11:06 ET | 578 | 3.205 |
11:08 ET | 1207 | 3.21 |
11:09 ET | 495 | 3.2161 |
11:11 ET | 7580 | 3.23 |
11:13 ET | 632 | 3.225 |
11:15 ET | 1974 | 3.23 |
11:18 ET | 1404 | 3.235 |
11:22 ET | 400 | 3.235 |
11:24 ET | 9918 | 3.215 |
11:26 ET | 2636 | 3.225 |
11:27 ET | 1243 | 3.22 |
11:29 ET | 14870 | 3.2 |
11:31 ET | 600 | 3.205 |
11:33 ET | 100 | 3.21 |
11:36 ET | 252 | 3.21 |
11:38 ET | 200 | 3.205 |
11:40 ET | 200 | 3.205 |
11:42 ET | 500 | 3.2033 |
11:45 ET | 200 | 3.2012 |
11:47 ET | 1100 | 3.205 |
11:49 ET | 400 | 3.205 |
11:51 ET | 2818 | 3.2165 |
11:54 ET | 300 | 3.215 |
11:56 ET | 500 | 3.22 |
11:58 ET | 762 | 3.2113 |
12:00 ET | 1700 | 3.215 |
12:02 ET | 4131 | 3.225 |
12:03 ET | 9867 | 3.225 |
12:05 ET | 458 | 3.225 |
12:07 ET | 4430 | 3.215 |
12:09 ET | 841 | 3.215 |
12:12 ET | 200 | 3.215 |
12:14 ET | 100 | 3.2175 |
12:16 ET | 7100 | 3.22 |
12:18 ET | 100 | 3.215 |
12:20 ET | 400 | 3.215 |
12:21 ET | 200 | 3.22 |
12:23 ET | 600 | 3.215 |
12:25 ET | 700 | 3.215 |
12:27 ET | 300 | 3.215 |
12:30 ET | 9896 | 3.215 |
12:32 ET | 700 | 3.22 |
12:34 ET | 300 | 3.22 |
12:36 ET | 500 | 3.215 |
12:38 ET | 200 | 3.22 |
12:39 ET | 400 | 3.22 |
12:41 ET | 2672 | 3.205 |
12:43 ET | 100 | 3.205 |
12:45 ET | 4910 | 3.185 |
12:48 ET | 2463 | 3.175 |
12:50 ET | 600 | 3.18 |
12:52 ET | 722 | 3.17 |
12:54 ET | 300 | 3.17 |
12:56 ET | 700 | 3.17 |
12:57 ET | 776 | 3.1775 |
12:59 ET | 2946 | 3.17 |
01:01 ET | 200 | 3.175 |
01:06 ET | 781 | 3.175 |
01:08 ET | 325 | 3.18 |
01:10 ET | 300 | 3.175 |
01:12 ET | 100 | 3.175 |
01:14 ET | 3976 | 3.19 |
01:15 ET | 502 | 3.185 |
01:17 ET | 4044 | 3.175 |
01:19 ET | 1313 | 3.165 |
01:21 ET | 400 | 3.17 |
01:24 ET | 11767 | 3.165 |
01:26 ET | 100 | 3.165 |
01:28 ET | 454 | 3.1651 |
01:30 ET | 700 | 3.165 |
01:32 ET | 4649 | 3.155 |
01:33 ET | 6666 | 3.145 |
01:35 ET | 400 | 3.145 |
01:37 ET | 4047 | 3.14 |
01:39 ET | 2530 | 3.125 |
01:42 ET | 3076 | 3.125 |
01:44 ET | 3423 | 3.115 |
01:46 ET | 2988 | 3.115 |
01:48 ET | 4346 | 3.115 |
01:50 ET | 300 | 3.112 |
01:51 ET | 8224 | 3.105 |
01:53 ET | 300 | 3.1 |
01:55 ET | 12417 | 3.105 |
01:57 ET | 372 | 3.105 |
02:00 ET | 15872 | 3.1 |
02:02 ET | 6317 | 3.1 |
02:04 ET | 77321 | 3.09 |
02:06 ET | 5700 | 3.09 |
02:08 ET | 3813 | 3.105 |
02:09 ET | 1919 | 3.115 |
02:11 ET | 1500 | 3.1 |
02:13 ET | 548 | 3.105 |
02:15 ET | 2016 | 3.105 |
02:18 ET | 300 | 3.1 |
02:20 ET | 6746 | 3.085 |
02:22 ET | 1315 | 3.08 |
02:24 ET | 1100 | 3.08 |
02:26 ET | 1000 | 3.07 |
02:27 ET | 594 | 3.075 |
02:29 ET | 5634 | 3.075 |
02:31 ET | 570 | 3.07 |
02:33 ET | 1540 | 3.07 |
02:36 ET | 6475 | 3.075 |
02:38 ET | 203 | 3.075 |
02:40 ET | 400 | 3.075 |
02:42 ET | 4654 | 3.075 |
02:44 ET | 1070 | 3.075 |
02:45 ET | 2200 | 3.07 |
02:47 ET | 300 | 3.065 |
02:49 ET | 1300 | 3.06 |
02:51 ET | 10501 | 3.06 |
02:54 ET | 1000 | 3.06 |
02:56 ET | 1000 | 3.07 |
02:58 ET | 8700 | 3.0601 |
03:00 ET | 1885 | 3.07 |
03:02 ET | 1750 | 3.07 |
03:03 ET | 703 | 3.07 |
03:05 ET | 2600 | 3.075 |
03:07 ET | 12240 | 3.075 |
03:09 ET | 1250 | 3.075 |
03:12 ET | 500 | 3.075 |
03:14 ET | 618 | 3.0775 |
03:16 ET | 1100 | 3.07 |
03:18 ET | 1800 | 3.07 |
03:20 ET | 700 | 3.07 |
03:21 ET | 34337 | 3.065 |
03:23 ET | 418 | 3.065 |
03:27 ET | 4477 | 3.06 |
03:30 ET | 100 | 3.065 |
03:32 ET | 626 | 3.065 |
03:34 ET | 3416 | 3.065 |
03:36 ET | 300 | 3.065 |
03:38 ET | 12973 | 3.065 |
03:39 ET | 39889 | 3.045 |
03:41 ET | 9965 | 3.035 |
03:43 ET | 14945 | 3.05 |
03:45 ET | 43410 | 3.045 |
03:48 ET | 837 | 3.045 |
03:50 ET | 2150 | 3.045 |
03:52 ET | 3755 | 3.045 |
03:54 ET | 10131 | 3.055 |
03:56 ET | 10730 | 3.065 |
03:57 ET | 10206 | 3.07 |
03:59 ET | 20542 | 3.08 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 810.7M | -9.8x | --- |
Viridian Therapeutics Inc | 810.5M | -2.7x | --- |
Disc Medicine Inc | 820.0M | -9.9x | --- |
CARGO Therapeutics Inc | 827.3M | -7.2x | --- |
ProKidney Corp | 838.7M | -6.2x | --- |
ALX Oncology Holdings Inc | 781.5M | -4.0x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $810.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.44 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.